[en] The pathophysiology and the treatment of diseases with clinical presentation so
different as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
and psoriasis vulgaris have been revolutionized by the discovery of common
pro-inflammatory effector mechanisms involving TNF-alpha and by the use of
targeted therapies, the anti-TNF-alpha antibodies. In the past 10 years, our
experience has helped several hundreds of patients who were treated with novel
drugs, years before they became routinely available. In parallel tools of
metrology were developped that can now be applied to the routine patient. Lastly,
clinical research on these new drugs has also generated derived research works
allowing the university hospital to satisfactorilly fullfil its specific
missions.
Aggarwal BB, Kohr WJ, Hass PE, et al. - Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem, 1985, 260, 2345-2354.
Beutler B, Mahoney J, Le Trang N, et al. - Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med, 1985, 161, 984-995.
Beutler B, Greenwald D, Hulmes JD, et al. - Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature, 1985, 316, 552-554.
Beutler B, Mahoney J, Le Trang N, et al. - Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med, 1985, 161, 984-995.
Dayer JM, Beutler B, Cerami A. - Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med, 1985, 162, 2163-2168.
Elliott MJ, Maini RN, Feldmann M, et al. - Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum, 1993, 36, 1681-1690.
Moreland LW, Baumgartner SW, Schiff MH, et al. - Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med, 1997, 337, 141-147.
Prevoo ML, van't Hof MA, Kuper HH, et al. - Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum, 1995, 38, 44-48.
9a. Felson DT, Anderson JJ, Boers M, et al. - American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38, 727-735.
9b. Garrett S, Jenkinson T, Kennedy LG, et al. - A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol, 1994, 21, 2286-2291.
Anderson JJ, Baron G, van der Heijde D, et al. - Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum, 2001, 44, 1876-1886.
Fredriksson T, Pettersson U. - Severe psoriasis - oral therapy with a new retinoid. Dermatologica, 1978, 157, 238-244.
Gasche C, Scholmerich J, Brynskov J, et al. - A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis, 2000, 6, 8-15.
Siegert CE, Vleming LJ, Vandenbroucke JP, et al. - Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol, 1984, 3, 305-309.
Calin A, Garrett S, Whitelock H, et al. - A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol, 1994, 21, 2281-2285.
Jenkinson TR, Mallorie PA, Whitelock HC, et al. - Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol, 1994, 21, 1694-1698.
van Gestel AM, Prevoo ML, van 't Hof MA, et al. - Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum, 1996, 39, 34-40.
van der Heijde D, Kivitz A, Schiff MH, et al. - Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 2006, 54, 2136-2146.
Clegg DO, Reda DJ, Mejias E, et al. - Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 1996, 39, 2013-2020.
Ribbens C, Martin y Porras M, Franchimont N, et al. - Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis, 2002, 61, 161-166.
van der Heijde D. - How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol, 2000, 27, 261-263.
Kavanaugh A, Antoni CE, Gladman D, et al. - The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) : results of radiographic analyses after 1 year. Ann Rheum Dis, 2006, 65, 1038-1043.
MacKay K, Mack C, Brophy S, et al. - The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum, 1998, 41, 2263-2270.
Wanders AJ, Landewe RB, Spoorenberg A, et al. - What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum, 2004, 50, 2622-2632.
Kirwan JR. - Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol, 1999, 26, 720-725.
Maini RN, Breedveld FC, Kalden JR, et al. - Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 2004, 50, 1051-1065.
St Clair EW, van der Heijde DM, Smolen JS, et al. - Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum, 2004, 50, 3432-3443.
Klareskog L, van der Heijde D, de Jager JP, et al. - Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 2004, 363, 675-681.
van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. - Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum, 2006, 54, 1063-1074.
Keystone EC, Kavanaugh AF, Sharp JT, et al. - Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum, 2004, 50, 1400-1411.
Smolen JS, Han C, Bala M, et al. - Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum, 2005, 52, 1020-1030.
Smolen JS, Van Der Heijde DM, St Clair EW, et al. - Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum, 2006, 54, 702-710.
Landewe R, van der Heijde D, Klareskog L, et al. - Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum, 2006, 54, 3119-3125.
Emery P, Genovese M, Van Vollenhoven R, et al. - Less progression of joint erosion (JE) and joint space narrowing (JSN) with adalimumab plus MTX vs MTX monotherapy at all levels of clinical response : subanalysis of PREMIER. Ann Rheum Dis, 2007, 66, 169.
van der Heijde D, Kavanaugh A, Gladman DD, et al. - Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum, 2007, 56, 2698-2707.
Mease PJ, Kivitz AJ, Burch FX, et al. - Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum, 2004, 50, 2264-2272.
Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum, 2005, 52, 3279-3289.
Lipsky PE, van der Heijde DM, St Clair EW, et al. - Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000, 343, 1594-1602.
Hallert E, Husberg M, Jonsson D, et al. - Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology, 2004, 43, 1374-1382.
Smolen JS, Han C, van der Heijde D, et al. - Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum, 2006, 54, 716-722.
van der Heijde D, Han C, DeVlam K, et al. - Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum, 2006, 55, 569-574.
Kavanaugh A, Antoni C, Mease P, et al. - Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol, 2006, 33, 2254-2259.
Lichtenstein GR, Yan S, Bala M, et al. - Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol, 2004, 99, 91-96.
Reinisch W, Sandborn WJ, Bala M, et al. - Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis, 2007, 13, 1135-1140.
Yelin E, Trupin L, Katz P, et al. - Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum, 2003, 48, 3046-3054.
Kimball AB, Jackson JM, Sobell JM, et al. - Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol, 2007, 6, 299-306.
Bejarano V, Quinn MA, Conaghan PG, et al. - Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis : result of the prevention of work disability (PROWD) study. Ann Rheum Dis, 2007, 66, 176.
van de Putte LB, Rau R, Breedveld FC, et al. - Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis, 2003, 62, 1168-1177.
van de Putte LB, Atkins C, Malaise M, et al. - Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis, 2004, 63, 508-516.
Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. - A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis, 2006, 65, 1578-1584.
Burmester GR, Mariette X, Montecucco C, et al. - Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis, 2007, 66, 732-739.
Ribbens C, Andre B, Marcelis S, et al. - Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study. Radiology, 2003, 229, 562-569.
Beckers C, Ribbens C, Andre B, et al. - Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med, 2004, 45, 956-964.
Beckers C, Jeukens X, Ribbens C, et al. - (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging, 2006, 33, 275-280.
Geurts P, Fillet M, de Seny D, et al. - Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics, 2005, 21, 3138-3145.
de Seny D, Fillet M, Meuwis MA, et al. - Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum, 2005, 52, 3801-3812.
Franchimont N, Putzeys V, Collette J, et al. - Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther, 2004, 20, 607-614.
Rausin A, Henno A, de la Brassine M. - Biological agents in the treatment of psoriasis. G Ital Dermatol Venereol, 2005, 140, 557-560.